公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US11248043B2

公开(公告)日：2022-02-15

申请号：US16919032

申请日：2020-07-01

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: G01N33/53 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C07K16/00 ,  C12P21/08 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US10738110B2

公开(公告)日：2020-08-11

申请号：US16246326

申请日：2019-01-11

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  A61K49/00 ,  A61K49/16 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US12054527B2

公开(公告)日：2024-08-06

申请号：US16620029

申请日：2019-04-08

Applicant: Amgen Inc.

Inventor： YuMei Xiong ,  Kenneth William Walker ,  Murielle Marie Veniant Ellison

IPC: C07K14/495 ,  A61K38/00

CPC classification number: C07K14/495 ,  A61K38/00 ,  C07K2319/30

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

公开(公告)号：US11161889B2

公开(公告)日：2021-11-02

申请号：US17148761

申请日：2021-01-14

Applicant: Amgen Inc.

Inventor： YuMei Xiong ,  Kenneth William Walker ,  Murielle Marie Veniant Ellison

IPC: C07K14/495

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

公开(公告)号：US10894814B2

公开(公告)日：2021-01-19

申请号：US15826442

申请日：2017-11-29

Applicant: Amgen Inc.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Z. Sheng ,  Agnes Eva Hamburger ,  Murielle M. Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Marissa Mock ,  Kenneth William Walker

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.